Biotech Values

[mcbio]

ARRY - The melanoma data was expected end of june according to one analyst so i presumed the run up was due to that. I'm surprised the pain trial results caused a 15 % drop. The only reason I can think of is that 797 is fully owned and perhaps there was the possibility that it could also be faster to market than any of the other drugs.

ARRY believes ARRY-614 will be in pivotal trials next year, it remains wholly-owned, and ARRY has disclosed it intends to take the drug to market themselves. They also claim, if you believe management, that the MDS patient population that they are targeting with 614 is a $1B opportunity with no competition. So, 614 is a much, much bigger opportunity than 797 (ARRY intends to partner 797 and would thus have to share economics there) and it's about as close to market as 797 if you trust management's guidance. Obviously they need to deliver on the data, starting at ASH in December.